Keyphrases
Mesenchymal Stem Cells
100%
Immune Regulation
100%
Combination Treatment
45%
Triple Combination
45%
Graft-versus-host Disease (GvHD)
27%
Interleukin-6
18%
Immunomodulatory
18%
Leukemia Inhibitory Factor
18%
Kynurenine
18%
Mouse Model
9%
Autoimmune Disease
9%
Cyclooxygenase-2
9%
Inducible Nitric Oxide Synthase
9%
Clinical Trials
9%
Lymphocytes
9%
Etiology
9%
Receptor Activation
9%
Disease Symptoms
9%
Regulatory Function
9%
Programmed Death-ligand 1 (PD-L1)
9%
Systemic Disease
9%
Immune Disorders
9%
Immunomodulatory Activity
9%
High Diversity
9%
Cell Therapy
9%
Disease Score
9%
Aryl Hydrocarbon Receptor
9%
Regulatory Phenotype
9%
Mouse Survival
9%
Single Administration
9%
Heme oxygenase-1 (HO-1)
9%
Cyclooxygenase-2 Expression
9%
Th17 Cell Differentiation
9%
Indoleamine 2,3-dioxygenase 1 (IDO1)
9%
Graft-versus-host Disease Prophylaxis
9%
Organ Rejection
9%
Immunology and Microbiology
Immunity
100%
Mesenchymal Stem Cell
100%
Graft-Versus-Host Disease
36%
Interleukin 6
18%
Leukemia Inhibitory Factor
18%
Secretion (Process)
9%
Autoimmune Disease
9%
Mouse Model
9%
Upregulation
9%
Downregulation
9%
Coculture
9%
Programmed Death 1 Ligand 1
9%
Transplant Rejection
9%
Indoleamine 2,3-dioxygenase
9%
Heme
9%
Lymphocyte
9%
Immune System Disorders
9%